Siplizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Siplizumab
Accession Number
DB06371
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
Not Available
Protein structure
Db06371
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
MEDI-507
Categories
UNII
KUW1QG1ZM3
CAS number
288392-69-8

Pharmacology

Indication

Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).

Pharmacodynamics
Not Available
Mechanism of action

Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.

TargetActionsOrganism
UT-cell surface antigen CD2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Siplizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Siplizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Siplizumab.
AducanumabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Siplizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siplizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Siplizumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Siplizumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Siplizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentGamma Delta Hepatosplenic T-Cell Lymphoma / NK T-Cell Lymphoma / Subcutaneous Panniculitis-Like T-Cell Lymphoma / T-Cell Peripheral Lymphoma1
1CompletedTreatmentGraft Versus Host Disease (GVHD)2
1CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies1
1CompletedTreatmentKidney Diseases1
1TerminatedTreatmentLeukemias / Malignancies / Malignant Lymphomas1
1TerminatedTreatmentLymphoproliferative Disorders1
1, 2Active Not RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
2CompletedTreatmentChronic Renal Failure (CRF) / Transplantation, Kidney1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
CD2 interacts with lymphocyte function-associated antigen (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytopla...
Gene Name
CD2
Uniprot ID
P06729
Uniprot Name
T-cell surface antigen CD2
Molecular Weight
39447.96 Da

Drug created on March 19, 2008 10:27 / Updated on November 02, 2018 06:16